🇺🇸 FDA
Company

Tarsus

Tarsus Pharmaceuticals

TARS biotech USA

Quick answer

Tarsus is a biotech company (TARS) headquartered in IRVINE, CA, USA with 14 tracked pipeline programs.

Pipeline (14)

project

TP-03

Blepharitis

Phase 3 · small_molecule · completed

1 trials project

TP-03, 0.25%

Blepharitis

Phase 3 · small_molecule · completed

1 trials project

Lotilaner Gel, 2.0%

Papulopustular Rosacea

Phase 2 · small_molecule · completed

1 trials project

Low Dose TP-05

Healthy Volunteer

Phase 2 · small_molecule · completed

1 trials project

TP-03

Meibomian Gland Dysfunction

Phase 2 · small_molecule · completed

1 trials project

TP-05 (lotilaner) Low Dose

Lyme Disease

Phase 2 · small_molecule · active

1 trials project

Vehicle of TP-03

Meibomian Gland Dysfunction

Phase 2 · small_molecule · active

1 trials project

lotilaner

Ocular Rosacea

Phase 2 · small_molecule · active

1 trials project

TP-03 (Lotilaner Ophthalmic Solution), 0.25%

Healthy

Phase 1 · small_molecule · completed

1 trials project

TP-05 (lotilaner oral capsules)

Healthy

Phase 1 · small_molecule · completed

1 trials project

TP-05 (lotilaner oral), fasted group

Healthy

Phase 1 · small_molecule · completed

1 trials project

Lotilaner ophthalmic solution, 0.25%

Demodex Blepharitis

Approved · small_molecule · completed

1 trials project

Standart medical treatment

High Intensity Interval Training

Unknown · small_molecule · active

1 trials project

Uteratonic administration

Placenta Abruptio

Unknown · small_molecule · active

1 trials

Drugs (1)

drug

lotilaner

XDEMVY

Patents (8)

patent

US 12364685

Isoxazoline parasiticide formulations

Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12257263

Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12213964

Isoxazoline parasiticide formulations

Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12171750

Isoxazoline parasiticide formulations and methods for treating blepharitis

Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11752137

Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11690826

Methods for treating demodex blepharitis using lotilaner formulations

Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11690827

Methods for treating ocular Demodex using lotilaner formulations

Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11197847

Isoxazoline parasiticide formulations and methods for treating blepharitis

Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)